Effect of reboxetine and citalopram on anal opening pressure in healthy women: A randomized, double-blind, placebo-controlled crossover study.
Thea ChristoffersenTroels RiisJesper SonneJonatan KornholtDavid P SonneNiels KlarskovPublished in: Neurogastroenterology and motility (2024)
An 8-mg dose of reboxetine increased anal opening pressure substantially in healthy women, suggesting potential benefits for fecal incontinence symptoms. In contrast, a 40-mg dose of citalopram showed a marginal and statistically insignificant effect on anal opening pressure, indicating that selective serotonin reuptake inhibitors do not contribute to fecal incontinence by reducing anal sphincter tone.
Keyphrases
- placebo controlled
- high grade
- double blind
- polycystic ovary syndrome
- urinary incontinence
- clinical trial
- pregnancy outcomes
- magnetic resonance
- phase ii
- study protocol
- randomized controlled trial
- squamous cell carcinoma
- skeletal muscle
- metabolic syndrome
- breast cancer risk
- insulin resistance
- sleep quality
- human health